A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion

Minovia

Status and phase: Withdrawn; Phase 1

Conditions: Primary Mitochondrial Diseases

Treatments: Procedure: Apheresis; Procedure: Bone Marrow mobilization; Biological: MNV-BM-PLC infusion

Study type: Interventional

Funder types: Industry

Identifiers

NCT04548843

PLC-PMD-01-IL

Details and patient eligibility

About

The study objectives are to evaluate the safety of a single intravenous (IV) infusion of autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria in participant with primary mitochondrial disease associated with mitochondrial DNA mutations or deletions.

6 participants aged from 4 to 18 years old on the day of screening visit with primary mitochondrial disease associated with mitochondrial DNA mutations or deletions will be enrolled.

Full description

MNV-BM-PLC is a personalized cell therapy based on autologous patient-derived Hematopoietic stem/progenitor cells (HSPCs) enriched with mitochondria isolated from healthy placenta obtained from donors during C-section. Healthy mitochondria are employed, ex-vivo, to enrich the patient's CD34+ peripheral blood cells, followed by infusion of the mitochondrial enriched cells back to the patient. This therapeutic process of mitochondrial augmentation provides the patient with healthy mitochondria carrying non-mutated/deleted mtDNA that can supplement mitochondrial functionality in the patient's cells.

Sex: All

Ages: 4 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Molecular diagnosis of primary mitochondrial disease
• Age between 4 years and up to 18 years, with a minimum body weight of 20 (+/-1) kilogram on the day of screening visit.
• Performance score: Karnofsky ≥40 (or equivalent in children younger than 16 years old.
• Patients or Patient's parents or legal guardian (where applicable) has a good understanding of the study and nature of the procedure and is willing and able to provide written informed consent prior to participation in any study-related procedures.
• Medical ability to undergo the study procedures safely, as determined by the investigator.

Exclusion Criteria

• Positive test for pathogenic agents .
• Inability to undergo leukapheresis, as determined by the investigator.
• Chronic severe infection or any other disease or condition that may risk the patient or interfere with the ability to interpret the study results.
• Known history of malignancy.
• Patient has been treated within the last one year prior to IP treatment with a different cell therapy.
• Patient has participated in another interventional clinical study and/or received other experimental medication outside of a clinical study within 1 month prior the day of Investigation product (IP) treatment visit.
• A pregnant or lactating woman or a woman who plans to become pregnant during the study. In addition, any woman of childbearing potential (not sterile or postmenopausal), who is unwilling to adhere to the use highly effective contraception method for the duration of the study
• In the opinion of the Investigator, the patient is unsuitable for participating in the study due to safety concerns.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Sequential Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Cohort 1 & Cohort 2

Experimental group

Description:

3 patients will be administrated with Dose 1 (0.88 mitochondria unit (mU) citrate synthase (CS) activity per million cells). 3 patients will be administrated with Dose 2 (4.4mU mitochondria unit (mU) citrate synthase (CS) activity per million cells).

Treatment:

Biological: MNV-BM-PLC infusion

Procedure: Bone Marrow mobilization

Procedure: Apheresis